The tobacco industry is relying on product and marketing innovation to drive future growth. The electronic or e- cigarette market provides a much needed area of growth for tobacco manufacturers, including the major cigarette manufacturers. The cigar market is another potential area for growth given the extensive variety of products available. E-cigarettes and cigars are not currently subject to the same FDA regulations as cigarettes and as result, the flavorings, product descriptors;and packaging in these markets vary more widely. In addition, the marketing strategies for e-cigarettes appear to highlight their potential for harm reduction. Such marketing will likely stimulate demand as well as questions to providers from patients about the safety of-cigarettes. Marketing of e-cigarettes has also become more mainstream as more brands are nationally advertised. Brand as well as flavor and packaging are also particularly important to cigar users. This revision application describes a plan to conduct three individual research projects that provide scientific data that can inform FDA regulation of e-cigarettes and cigars. These three projects respond to four of the FDA Center for Tobacco Products'research interest areas identified in the FOA including areas 2 (cigar use and perceptions), 4 (e-cigarette use and perceptions), 6 (impact of tobacco product characteristics on initiation) and 10 (effective communication strategies regarding the risk of tobacco products). Specifically, we plan to examine patient-provider communication related to e-cigarettes, explore the influence of ecigarette marketing on consumer perceptions and product trial, and investigate the impact of cigar product characteristics on young adults'cigar use and perceptions. Quantitative and qualitative data will be collected on the multiple factors that potentially influence the use of these products. Thus, the significance of this proposed research is its potential to generate a better understanding of e-cigarette and cigar use and perceptions which is vital to informing FDA tobacco product regulation.
The purpose of this application seeks to better understand and address the factors that impact perceptions and use of e-cigarettes and cigars. The relevance of the proposed research to public health is its ability to advance the evidence base to inform FDA tobacco product regulation.
|Cuellar-Partida, Gabriel; Lu, Yi; Dixon, Suzanne C et al. (2016) Assessing the genetic architecture of epithelial ovarian cancer histological subtypes. Hum Genet 135:741-56|
|Cannioto, Rikki A; LaMonte, Michael J; Kelemen, Linda E et al. (2016) Recreational physical inactivity and mortality in women with invasive epithelial ovarian cancer: evidence from the Ovarian Cancer Association Consortium. Br J Cancer 115:95-101|
|Manne, Sharon; Hudson, Shawna V; Baredes, Soly et al. (2016) Survivorship care experiences, information, and support needs of patients with oral and oropharyngeal cancer. Head Neck 38 Suppl 1:E1935-46|
|Stapleton, Jerod L; Hillhouse, Joel J; Turrisi, Rob et al. (2016) The Behavioral Addiction Indoor Tanning Screener (BAITS): An Evaluation of a Brief Measure of Behavioral Addictive Symptoms. Acta Derm Venereol 96:552-3|
|Qin, Bo; Moorman, Patricia G; Alberg, Anthony J et al. (2016) Dietary carbohydrate intake, glycaemic load, glycaemic index and ovarian cancer risk in African-American women. Br J Nutr 115:694-702|
|Viola, Adrienne S; Giovenco, Daniel P; Miller Lo, Erin J et al. (2016) A cigar by any other name would taste as sweet. Tob Control 25:605-6|
|Pan, Ji-An; Sun, Yu; Jiang, Ya-Ping et al. (2016) TRIM21 Ubiquitylates SQSTM1/p62 and Suppresses Protein Sequestration to Regulate Redox Homeostasis. Mol Cell 61:720-33|
|Zhang, Cen; Liu, Juan; Huang, Grace et al. (2016) Cullin3-KLHL25 ubiquitin ligase targets ACLY for degradation to inhibit lipid synthesis and tumor progression. Genes Dev 30:1956-70|
|Stapleton, Jerod L; Tatum, Kristina L; Devine, Katie A et al. (2016) Skin Cancer Surveillance Behaviors Among Childhood Cancer Survivors. Pediatr Blood Cancer 63:554-7|
|Spencer, Kristen R; Mehnert, Janice M (2016) Importance of including patients with comorbidities in clinical trials. Lancet Oncol 17:17-8|
Showing the most recent 10 out of 623 publications